Clinical Trial Update: Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating intermittent therapy in metastatic renal cell carcinoma patients treated with ipilimumab and nivolumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED